Peptide News Digest

#5-Million-Prescriptions

2 stories

Industry · View digest

Novo Nordisk (NYSE: NVO) Shares Fell Approximately 5% Tuesday-Wednesday Following the August 4 H1 2026 Earnings Release as CEO Lars Fruergaard Jorgensen Defended Wegovy Pill Economics on the Earnings Call While Analysts Focus on the Compressed Margin Trajectory From the Most-Favored-Nation Pricing Deals With the Trump Administration (November 2025) and the Medicare GLP-1 Bridge Program (Launched July 1) That Both Reduce Net Realized Prices Per Unit Even as Prescription Volume Climbs; Wegovy Pill Has Reached More Than 5 Million Cumulative US Prescriptions Since Q1 2026 Launch

Novo Nordisk (NYSE: NVO) shares fell approximately 5% across Tuesday and Wednesday August 4-5, 2026 following the H1 2026 earnings release. CEO Lars Fruergaard Jorgensen defended Wegovy pill economics on the earnings call, addressing analyst concerns about the compressed margin trajectory from the Most-Favored-Nation pricing deals announced with the Trump administration in November 2025 (which paired lower drug prices with expanded Medicare access and a three-year tariff grace period) and the Medicare GLP-1 Bridge Program launched July 1, 2026 (providing Wegovy, Zepbound KwikPen, and Foundayo at a capped $50/month copay for eligible Medicare Part D beneficiaries through December 31, 2027). Both programs reduce net realized prices per unit even as prescription volume climbs. Wegovy pill (oral semaglutide 25/50 mg for obesity) has reached more than 5 million cumulative US prescriptions since the Q1 2026 launch, one of the fastest oral obesity-drug uptake curves on record. Novo Nordisk H1 2026 sales reached 78.49 billion Danish kroner ($12.09 billion, +3% constant currency); the company raised full-year 2026 guidance from prior expectations to down 6% to flat at constant exchange rates. Analyst attention now focuses on 2027 pricing environment and Novo's ability to defend franchise economics as Eli Lilly's tirzepatide and orforglipron continue to widen the competitive gap.

Industry · View digest

Novo Nordisk Q2 2026 Earnings Tuesday August 4 Report Sales of 78.49 Billion Danish Kroner ($12.09 Billion, +3% Constant Currency, +7% Adjusted Sales); Wegovy Injectable Reached 19.484 Billion DKK (+1% YoY), Wegovy Pill (Oral Semaglutide 25/50 mg for Obesity, Launched Q1 2026) Generated 3.218 Billion DKK on More Than 5 Million Cumulative Prescriptions Since Launch, and Ozempic (Semaglutide for Type 2 Diabetes) Grew 3% to 31.375 Billion DKK; 2026 Adjusted Sales Guidance Hiked From Prior Range to Down 6% to Flat at Constant Exchange Rates on the Wegovy Pill Strength

Novo Nordisk reported Q2 2026 earnings Tuesday August 4, 2026 with sales of 78.49 billion Danish kroner ($12.09 billion, +3% constant currency, +7% adjusted). Franchise performance: Wegovy injectable reached 19.484 billion DKK (+1% year-over-year); Wegovy pill (oral semaglutide 25/50 mg for obesity, launched Q1 2026) generated 3.218 billion DKK on more than 5 million cumulative prescriptions since launch; Ozempic (semaglutide for type 2 diabetes) grew 3% to 31.375 billion DKK. Novo Nordisk hiked its 2026 adjusted sales guidance to down 6% to flat at constant exchange rates, an improvement from the previous guidance that had reflected the substantially compressed pricing environment from the Trump administration Most-Favored-Nation deals and the July 1 Medicare GLP-1 Bridge Program launch. The Wegovy pill launch trajectory (5 million prescriptions in roughly six months) is one of the fastest oral obesity-drug uptake curves on record and effectively confirms the strength of the SNAC-enhanced oral peptide formulation strategy that Novo has pursued since the 2019 Rybelsus approval for type 2 diabetes. Novo shares tanked despite the raised outlook, reflecting concern about the tough Q2 2025 comparison and margin trajectory into 2027.